Literature DB >> 17768110

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response.

Morie A Gertz1, Martha Q Lacy, Angela Dispenzieri, Suzanne R Hayman, Shaji K Kumar, Nelson Leung, Dennis A Gastineau.   

Abstract

Our objective was to determine whether the goal of high-dose therapy should be a partial hematologic response or a complete response. We analyzed 282 consecutive stem cell transplant patients. A partial hematologic response was achieved in 108 patients (38%), and 93 (33%) achieved a complete hematologic response. Survival rates of patients with complete, partial, or no response were significantly different (p<0.001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival.

Entities:  

Mesh:

Year:  2007        PMID: 17768110     DOI: 10.3324/haematol.11413

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  30 in total

1.  High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Authors:  Sumit Madan; Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; David Dingli; S Vincent Rajkumar; William J Hogan; Nelson Leung; Martha Grogan; Morie A Gertz
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

Review 2.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

3.  Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.

Authors:  S Hong; J Valent; L Rybicki; D Abounader; B Bolwell; R Dean; A T Gerds; D Jagadeesh; B K Hamilton; B Hill; M E Kalaycio; B Pohlman; F Reu; C Samaras; R Sobecks; N S Majhail; H D Liu
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

4.  Current treatment of AL amyloidosis.

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

5.  Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.

Authors:  Vaishali Sanchorawala; Karen Quillen; J Mark Sloan; Nancy T Andrea; David C Seldin
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

6.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

7.  Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Aimaz Afrough; Rima M Saliba; Amir Hamdi; Riad El Fakih; Ankur Varma; Yvonne T Dinh; Gabriela Rondon; A Megan Cornelison; Nina D Shah; Qaiser Bashir; Jatin J Shah; Chitra Hosing; Uday Popat; Robert Z Orlowski; Richard E Champlin; Simrit Parmar; Muzaffar H Qazilbash
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-02       Impact factor: 5.742

8.  Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.

Authors:  S W Wong; D Larivee; M Warner; K A Sprague; T Fogaren; R L Comenzo
Journal:  Bone Marrow Transplant       Date:  2017-04-10       Impact factor: 5.483

9.  Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.

Authors:  Shawn C Pun; Heather J Landau; Elyn R Riedel; Jonathan Jordan; Anthony F Yu; Hani Hassoun; Carol L Chen; Richard M Steingart; Jennifer E Liu
Journal:  J Am Soc Echocardiogr       Date:  2017-10-27       Impact factor: 5.251

Review 10.  Newer Therapies for Amyloid Cardiomyopathy.

Authors:  Rajshekhar Chakraborty; Eli Muchtar; Morie A Gertz
Journal:  Curr Heart Fail Rep       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.